Studies have demonstrated that inhibiting SREBP‐1 mRNA expression reduces cholesterol levels, alleviates hepatic steatosis, and improves adipose tissue hypertrophy, obesity, and insulin resistance. Here, SREBF1 is linked to Hepatic steatosis.